Druck Icon

Eckert & Ziegler increases earnings by 17%

Berlin, 8 May 2007. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for cancer radiation and radiometric systems, posted a surplus after taxes and minority distributions of 760,000 EUR or 0.24 EUR per share, representing an increase of 17% over last year's figure of 650,000 EUR (0.21 EUR per share). Overall group sales rose by 15% to 13 million EUR.

As in previous quarters and in spite of a recently unfavorable US dollar exchange rate development, the most profitable area was the Nuclear Medicine and Imaging segment, which contributed 560,000 EUR to the total surplus (last year: 360,000 EUR). The Therapy segment raised its earnings from 160,000 to 350,000 EUR, while the Radiopharmaceuticals segment, which is currently under development, posted a loss of 160,000 EUR. Sales in the Therapy segment represented an especially strong growth factor, benefiting from a large-scale contract for tumor radiation systems and rising volumes of prostate implants.

For the current business year, the Board anticipates sales of around 55 million EUR and profits of 2.8 million EUR (0.90 EUR per share).

Eckert & Ziegler is a globally active specialist for radiation applications in medicine, science and industry. Its main areas of activity are cancer therapy, nuclear medical diagnostics, and measurement technology. Listed on the Frankfurt Prime Standard (ISIN DE0005659700), the Group is headquartered in Berlin-Buch and has more than 300 employees. In addition to seven German sites, it has branch offices in Los Angeles, Atlanta, San Francisco, Prague, Paris, Milan, and Chennai (India).

The Board of Directors